EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Botanical Sources: 8

Danshen Salvia miltiorrhiza Bunge

Also called: dan shen, red sage, Chinese sage, Salviae miltiorrhizae radix et rhizoma

Danshen is the dried root and rhizome of Salvia miltiorrhiza, a perennial sage native to central and southern China and Vietnam. In China it is sold as tablets, dripping pills and injections; combination products are the most widely used.

Category
Botanical
Part used
Root and rhizome
Strongest evidence
C Limited
Native range
Native to central and southern China and Vietnam (POWO: "Central & S. China to Vietnam")
Reviewed
2026-10-29

Class 1 Well studied in people. EMA (2022) describes a 2018 meta-analysis pooling 10 RCTs (944 patients with angina) of Danshen injection (intravenous drip; composition not specified) added to antianginal drugs versus the drugs alone. Most trials in the Cochrane stroke and heart-attack reviews (sources 3-4) tested multi-herb formulas. [1]

Fact-checked 2026-10-29 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

3 topics studied2 body areas · strongest grade C

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Danshen does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Danshen, evidence grade and finding
Topic studiedGradeWhat the evidence shows
Acute ischemic stroke (Dan Shen agents)CCochrane (2007): six trials (494 patients), five of Compound Dan Shen (a combination product, per EMA) and five by injection, reported more neurological improvement, but all were of poor quality and reliable conclusions could not be drawn. [3]
Acute myocardial infarction (danshen preparations plus usual care)CCochrane (2008): six studies (2,368 participants), most testing multi-herb formulas (per EMA) and only one a genuine RCT; the evidence was too weak to judge effects and the safety of danshen preparations is unproven. [4]
Any use as a herbal medicinal product (EU review)CEMA (2022): most clinical studies had poor design, small samples and poorly defined products, so no plausibility or well-established use could be concluded. [1]

Main constituents: More than 200 compounds: lipophilic diterpenoid quinones of the tanshinone type (tanshinone I, IIA, IIB, cryptotanshinone) and hydrophilic phenolic acids (salvianolic acids, danshensu) [1]

Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Pregnancy and breastfeeding
    EMA cites a TCM reference text listing danshen as contraindicated in pregnancy and another source contraindicating it in pregnancy and breastfeeding …

    1 statement in the profile.

    Details and sources
  • Interactions with medicines
    5 listed

    Warfarin; Warfarin; Aspirin, heparin, clopidogrel, NSAIDs; Digoxin, cardiac glycosides, antihypertensives, beta-blockers …

    Details and sources
  • Cancer evaluations (IARC, NTP)
    None found

    No IARC or NTP evaluation was found in the lists checked.

    Details and sources
  • FDA new dietary ingredient notifications
    2 on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    None found

    No published information found in the sources checked.

    Details and sources
  • Known from traditional use: increased bleeding risk (skin or mucous-membrane bleeding, excessive menstrual bleeding), low blood pressure, dizziness, headache, itching, abdominal discomfort and anaphylactic reactions. [1]
  • EMA: the clinical safety of high-dose single-herb preparations is not established, and there are safety concerns about bleeding after intravenous use. [1]
  • A TCM reference text cited by EMA lists danshen as contraindicated in pregnancy; another cited source contraindicates it in pregnancy and breastfeeding because of anticoagulant activity. [1]
Interactions

Interactions

Danshen
From the table below 5 interactions the sources name. Tap one to read what happens. A line means a documented or possible interaction, not its size.
Known interactions of Danshen
WithWhat happens
WarfarinCase reports describe over-anticoagulation and bleeding, including an INR rise from 2.0 to above 5.5; a source cited by EMA advises avoiding danshen with warfarin. [1]
WarfarinBleeding when warfarin is combined with danshen is listed among plausible herb-drug interactions. [5]
Aspirin, heparin, clopidogrel, NSAIDsDanshen may increase bleeding risk with other drugs that share this side effect. [1]
Digoxin, cardiac glycosides and blood pressure drugsMay increase digoxin toxicity and affect its blood levels; excessive hypotension may occur with antihypertensives, and bradycardia with beta-blockers. [1]
CYP3A substrates (e.g., midazolam)In 12 healthy volunteers, 14 days of danshen tablets suggested induction of CYP3A4 in the gut; EMA advises caution with drugs metabolized by CYP3A. [1]

Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.

Quality

Identity, quality and standardization

  • European Pharmacopoeia (as cited by EMA): dried rhizome and root with at least 3.0% salvianolic acid B and 0.12% tanshinone IIA (C19H18O3). [1]
  • In one market study cited by EMA, 7 of 28 danshen-labeled final products were highly likely to contain no danshen root; substitutes such as Salvia przewalskii are sometimes sold as danshen. [1]
Regulation

Regulatory status

  • US: FDA states that, by law, it does not approve dietary supplements before they are marketed; firms are responsible for the safety and labeling of their products. [8]
  • EU: in 2022 the HMPC concluded that an EU herbal monograph on danshen root and rhizome cannot be established. [2]
  • Canada: Salvia miltiorrhiza root and rhizome (dan shen) is listed in Health Canada's Traditional Chinese Medicine Ingredients monograph (May 29, 2026). [7]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Tanshinones (tanshinone I, IIA, IIB, cryptotanshinone) Diterpenoid quinones [P3]
  • Salvianolic acids and danshensu Phenolic acids [P3]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • FDA's published NDI notification list has 2 entries naming danshen or Salvia miltiorrhiza (earliest NDI 42 submitted 1998-11-13, danshen root; most recent NDI 1172 submitted 2020-08-14, a three-herb combination). Each entry is one party's notification; the list gives the date of FDA's response letter but not what it said. [P1]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • No IARC classification of danshen (Salvia miltiorrhiza root and rhizome) was found in the IARC Monographs list of classifications (Volumes 1–142, list updated 2026-07-23; checked 2026-10-29). [P2]
  • No NTP technical report (2-year study) on danshen (Salvia miltiorrhiza root and rhizome) was found in NTP's list of technical reports (checked 2026-10-29). [P6]

Liver (NIH LiverTox)

  • No published information found in the sources checked.

Interactions with medicines

  • Warfarin: EMA (2022): clinical case reports of over-anticoagulation and bleeding (e.g., INR from 2.0 to above 5.5); danshen has been shown to slow warfarin metabolism and a cited source advises avoiding the combination. [P3]
  • Warfarin: Listed among plausible herb-drug interactions causing bleeding (Lancet review, 2000). [P4]
  • Aspirin, heparin, clopidogrel, NSAIDs: May increase bleeding risk. [P3]
  • Digoxin, cardiac glycosides, antihypertensives, beta-blockers: Possible increased digoxin toxicity, excessive hypotension, and bradycardia with beta-blockers. [P3]
  • CYP3A substrates (e.g., midazolam): EMA (2022): a 14-day study in 12 healthy volunteers suggested danshen tablets induce gut CYP3A4; caution advised with CYP3A-metabolized drugs. [P3]

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • EMA (2022) cites an NMR/HPTLC market study of 97 samples: 7 of 28 final products were highly likely to contain no danshen root, and 6 online sources contained neither salvianolic acid B nor tanshinone IIA; local substitutes include Salvia przewalskii, S. bowleyana and S. sinica. [P3]

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity test or examination of each component that is a dietary ingredient — Required by 21 CFR 111.75(a)(1)(i) unless FDA grants an exemption petition under 111.75(a)(1)(ii) [P5]
  • Salvianolic acid B and tanshinone assay — European Pharmacopoeia minimums (3.0% salvianolic acid B; 0.12% tanshinone II); market products found lacking both markers [P3]
  • Species identity (1H-NMR or HPTLC fingerprint) — Substitution with other Salvia species reported [P3]

Supply and conservation

  • No published information found in the sources checked.

Absorption in people

  • No published information found in the sources checked.

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • No published information found in the sources checked.

Pregnancy and breastfeeding

  • EMA cites a TCM reference text listing danshen as contraindicated in pregnancy and another source contraindicating it in pregnancy and breastfeeding because of anticoagulant activity; effects on the fetus or nursing infant are unknown. [P3]

Sources for this profile

  1. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  2. IARC Monographs. List of Classifications (checked 2026-10-29), 2026-10-29. monographs.iarc.who.int
  3. EMA, HMPC. Assessment report on Salvia miltiorrhiza Bunge, radix et rhizoma. EMA/HMPC/509932/2019 (30 March 2022), 2022-03-30. ema.europa.eu
  4. Fugh-Berman A. Herb-drug interactions. Lancet 2000;355(9198):134-8 (PMID 10675182), 2000-01-08. pubmed.ncbi.nlm.nih.gov
  5. eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
  6. National Toxicology Program. Technical Reports (list of TR studies; checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
Sources

Sources

  1. EMA, HMPC. Assessment report on Salvia miltiorrhiza Bunge, radix et rhizoma. EMA/HMPC/509932/2019 (30 March 2022), 2022-03-30. ema.europa.eu
  2. EMA, HMPC. Public statement on Salvia miltiorrhiza Bunge, radix et rhizoma. EMA/HMPC/509931/2019 (30 March 2022), 2022-03-30. ema.europa.eu
  3. Wu B, Liu M, Zhang S. Dan Shen agents for acute ischaemic stroke. Cochrane Database Syst Rev 2007;(2):CD004295 (PMID 17443544), 2007-04-18. pubmed.ncbi.nlm.nih.gov
  4. Wu T, Ni J, Wu J. Danshen (Chinese medicinal herb) preparations for acute myocardial infarction. Cochrane Database Syst Rev 2008;(2):CD004465 (PMID 18425903), 2008-04-16. pubmed.ncbi.nlm.nih.gov
  5. Fugh-Berman A. Herb-drug interactions. Lancet 2000;355(9198):134-8 (PMID 10675182), 2000-01-08. pubmed.ncbi.nlm.nih.gov
  6. Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data. Salvia miltiorrhiza Bunge (accessed 2026-10-29; native range: "Central & S. China to Vietnam"), 2026-10-29. powo.science.kew.org
  7. Health Canada, NNHPD. Traditional Chinese Medicine Ingredients monograph (date May 29, 2026), 2026-05-29. webprod.hc-sc.gc.ca
  8. U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.